Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model.
HuH-7
drug delivery system
electrospun nanofiber sheet
lenvatinib
poly ε-caprolactone
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
15 Apr 2022
15 Apr 2022
Historique:
received:
23
02
2022
revised:
31
03
2022
accepted:
13
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Lenvatinib has a high response rate in unresectable advanced hepatocellular carcinoma (HCC). In this study, we investigated whether lenvatinib-incorporating poly(ε-caprolactone) sheets (lenvatinib sheets) as a drug delivery system (DDS) exerted antitumor effects in a murine HCC model. The lenvatinib sheets were designed for sustained release of approximately 1 mg lenvatinib for 14 days. For 14 days, 1 mg lenvatinib was orally administered to mice. Then, we compared the antitumor effects of lenvatinib sheets with those of oral lenvatinib. The tumor volume, body weight, and serum lenvatinib level were measured for 14 days. A peritoneal dissemination model was established to examine the survival prolongation effect of the lenvatinib sheets. Tumor growth was significantly inhibited in the lenvatinib sheet group compared with that in the no treatment and oral groups. The antitumor effect was significantly higher in the lenvatinib sheet group. Regardless of the insertion site, the serum lenvatinib levels were maintained and showed similar antitumor effects. The mitotic index was significantly inhibited in the lenvatinib sheet group compared with that in the control group. Furthermore, lenvatinib sheets improved the 30-day survival. Lenvatinib sheets showed sufficient antitumor effects and may serve as an effective novel DDS for advanced HCC.
Identifiants
pubmed: 35458072
pii: nano12081364
doi: 10.3390/nano12081364
pmc: PMC9025678
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Pharmaceutics. 2021 Nov 08;13(11):
pubmed: 34834304
Acta Biomater. 2017 Apr 15;53:250-259
pubmed: 28179161
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
J Clin Pharmacol. 2017 Sep;57(9):1138-1147
pubmed: 28561918
Polymers (Basel). 2018 Sep 13;10(9):
pubmed: 30960944
Polymers (Basel). 2021 Oct 10;13(20):
pubmed: 34685230
Cancer Sci. 2017 Apr;108(4):763-771
pubmed: 28107584
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Lancet. 2016 Feb 6;387(10018):545-557
pubmed: 26615328
J Control Release. 2021 Dec 10;340:48-59
pubmed: 34695523
Small. 2019 Nov;15(45):e1903060
pubmed: 31599125
Med Oncol. 2019 Mar 27;36(5):39
pubmed: 30919115
Clin Cancer Res. 2018 Jan 1;24(1):43-51
pubmed: 29030354
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Polymers (Basel). 2021 Oct 30;13(21):
pubmed: 34771316
J Clin Oncol. 2018 Jul 1;36(19):1922-1929
pubmed: 29746229
Adv Healthc Mater. 2019 Jul;8(13):e1900102
pubmed: 31091019
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Med. 2018 Jun;7(6):2641-2653
pubmed: 29733511
Clin Cancer Res. 2021 Nov 1;27(21):5771-5780
pubmed: 34426442
Hepatol Res. 2018 Jul;48(8):597-607
pubmed: 29689631
Drug Dev Ind Pharm. 2011 Sep;37(9):1068-75
pubmed: 21449700
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Exp Cell Res. 2021 Jan 1;398(1):112390
pubmed: 33227314
Ultrason Sonochem. 2021 Dec;80:105805
pubmed: 34706321
J Gastroenterol. 2017 Apr;52(4):512-519
pubmed: 27704266
Plast Reconstr Surg Glob Open. 2019 Dec 12;7(12):e2538
pubmed: 32537295